Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis

Olanzapine-induced dyslipidemia significantly increases the risk of cardiovascular disease in patients with schizophrenia. However, the clinical features of olanzapine-induced dyslipidemia remain hitherto unclear because of inconsistencies in the literature. This meta-analysis thus investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Rong, Zhang, Yiqi, Zhu, Wenqiang, Ding, Chen, Dai, Wenjie, Su, Xin, Dai, Wen, Xiao, Jingmei, Xing, Zhenhua, Huang, Xiansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552389/
https://www.ncbi.nlm.nih.gov/pubmed/33046806
http://dx.doi.org/10.1038/s41598-020-73983-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552389/
https://www.ncbi.nlm.nih.gov/pubmed/33046806
http://dx.doi.org/10.1038/s41598-020-73983-4

Ejemplares similares